Announcements Trials
Browse Landscape

Phase

Phase 2 5Phase 1/2 2Phase 3 1

Status

Recruiting 5Completed 5Unknown 3Terminated 3Not yet recruiting 1

Sponsor Class

OTHER 4INDUSTRY 1

Study Type

Interventional 5

Sponsor

Cancer Type

Breast 5

Conditions

Breast Neoplasms 305Carcinoma, Non-Small-Cell Lung 287Colorectal Neoplasms 159Prostatic Neoplasms 158Carcinoma, Hepatocellular 144Neoplasms 137Leukemia, Myeloid, Acute 131Lung Neoplasms 117Squamous Cell Carcinoma of Head and Neck 108Multiple Myeloma 104Triple Negative Breast Neoplasms 102Recurrence 101Pancreatic Neoplasms 96Stomach Neoplasms 94Ovarian Neoplasms 89Neoplasm Metastasis 87Lymphoma, Large B-Cell, Diffuse 81Sarcoma 70Esophageal Neoplasms 68Uterine Cervical Neoplasms 67Precursor Cell Lymphoblastic Leukemia-Lymphoma 67Melanoma 67Brain Neoplasms 67Rectal Neoplasms 64Head and Neck Neoplasms 62Glioblastoma 60Carcinoma, Renal Cell 58Myelodysplastic Syndromes 55Lymphoma 55Esophageal Squamous Cell Carcinoma 54

Interventions

dalpiciclib 2trastuzumab deruxtecan 1sacituzumab govitecan 1pegfilgrastim 1fluzoparib 1apatinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
Phase 2 × Recruiting × Breast Cancer Metastatic × Clear all
NCT06750484 2026-05-06

Trial of Trastuzumab Deruxtecan in Previously Treated HER2

Yale University

Phase 2 Recruiting
40 enrolled
Breast

Breast Cancer Metastatic

NCT06616987 2025-08-28

Prevention of Sacituzumab Govitecan-related Neutropenia in Patients With Metastatic Triple Negative Breast Cancer

Samsung Medical Center

Phase 2 Recruiting
40 enrolled
Breast

Breast Cancer Metastatic

NCT05420779 2024-05-08

A Study to Evaluate the Efficacy and Safety of TSL-1502 Capsules in Breast Cancer Patients With Germline BRCA Mutations

Tasly Pharmaceutical Group Co., Ltd

Phase 2 Recruiting
125 enrolled
Breast

Breast Cancer Metastatic

NCT05759546 2024-02-06

PARP Inhibitor With CDK4/6 Inhibitor and Endocrine Therapy in HR+/ HER2-Advanced Breast Cancer

Fudan University

Phase 2 Recruiting
200 enrolled
Breast

Breast Cancer Metastatic

NCT05759572 2024-02-06

Apatinib With CDK4/6 Inhibitor and Endocrine Therapy in HR+/ HER2- Advanced Breast Cancer

Fudan University

Phase 2 Recruiting
145 enrolled
Breast

Breast Cancer Metastatic

Data powered by HemOnc (CC BY 4.0) Colophon âš¡